Trial results

Semaglutide for Smoking Cessation in Patients With Diabetes

NCT07059377 on ClinicalTrials.gov · last registry update 2026-05-11

A small phase 3 — 100 participants, against a typical 424. Its estimated completion date, July 2026, has passed with no update to the record. Primary outcome, as filed: Project success. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Ottawa Heart Institute Research Corporation

Sponsor type

Other

Enrollment

100

Started

2026-02-13

Primary completion

2026-07 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Project success

Conditions studied

Diabetes Mellitus, Type 2 · Nicotine Addiction · Tobacco Dependence

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.